Outlook Therapeutics, Inc. (OTLK)
NASDAQ: OTLK · Real-Time Price · USD
1.440
+0.050 (3.60%)
At close: Dec 20, 2024, 4:00 PM
1.410
-0.030 (-2.08%)
After-hours: Dec 20, 2024, 5:00 PM EST
Company Description
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications.
Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018.
Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Outlook Therapeutics, Inc.
| Country | United States |
| Founded | 2010 |
| IPO Date | May 13, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 24 |
| CEO | Lawrence Kenyon |
Contact Details
Address: Building F, Suite 320 Iselin, New Jersey 08852 United States | |
| Phone | 609 619 3990 |
| Website | outlooktherapeutics.com |
Stock Details
| Ticker Symbol | OTLK |
| Exchange | NASDAQ |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0001649989 |
| CUSIP Number | 69012T206 |
| ISIN Number | US69012T3059 |
| Employer ID | 38-3982704 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Lawrence A. Kenyon CPA | EVice President, Chief Financial Officer, Interim Chief Executive Officer, Treasurer, Secretary and Director |
| Ralph H. Thurman | Executive Chairman |
| Jeffrey Evanson | Chief Commercial Officer |
| Joel Prieve | Senior Vice President of Licensing and M&A |
| Dr. Surendra Sharma M.D. | Senior Vice President of Medical Affairs |
| Dr. Jennifer M. Kissner Ph.D. | Senior Vice President of Clinical Development and Regulatory Affairs |
| Jedd Comiskey | Senior Vice President - Head of Europe |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 16, 2024 | 8-K | Current Report |
| Dec 4, 2024 | 8-K | Current Report |
| Nov 27, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Aug 14, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Aug 14, 2024 | 10-Q | Quarterly Report |
| Aug 14, 2024 | 8-K | Current Report |
| Jul 8, 2024 | 8-K | Current Report |
| Jun 26, 2024 | DEF 14A | Other definitive proxy statements |